• Vivani Medical completed enrollment and initial dosing in SLIM-1, a Phase 1 study of NPM-139, a long-acting semaglutide implant for chronic weight management.
• Results have not been presented; top-line data from the 20-participant trial is expected in November 2026.
• The trial is designed to assess safety, tolerability, and drug exposure, with a Wegovy injection group included for comparison.
• The program targets less frequent dosing to support adherence, with an implant designed for reversibility if treatment must be stopped.
• Management expects the Phase 1 readout to support a Phase 2 dose-ranging trial start in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.